Jason D Marshall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6159187/publications.pdf Version: 2024-02-01



IASON D MARSHALL

#	Article	IF	CITATIONS
1	Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. PLoS ONE, 2022, 17, e0271066.	2.5	17
2	Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists. Vaccine, 2021, 39, 292-302.	3.8	16
3	Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP. Human Vaccines and Immunotherapeutics, 2021, 17, 2748-2761.	3.3	11
4	Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccine. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 33, 102359.	3.3	13
5	Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gastroenterology, 2021, 161, 1288-1302.e13.	1.3	56
6	Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication. BMC Cancer, 2019, 19, 540.	2.6	27
7	Abstract 5090: Epitope mapping of mouse TERT for vaccine development. , 2019, , .		0
8	A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model. Vaccine, 2018, 36, 4023-4031.	3.8	25
9	Abstract LB-173: Epitope mapping of mTERT for vaccine development. , 2018, , .		0
10	Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir. Journal of Virology, 2017, 91, .	3.4	26
11	Feasibility of Freeze-Drying Oil-in-Water Emulsion Adjuvants and Subunit Proteins to Enable Single-Vial Vaccine Drug Products. Journal of Pharmaceutical Sciences, 2017, 106, 1490-1498.	3.3	23
12	Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery. MBio, 2017, 8, .	4.1	91
13	Development of a robust, higher throughput green fluorescent protein (GFP)-based Epstein-Barr Virus (EBV) micro-neutralization assay. Journal of Virological Methods, 2017, 247, 15-21.	2.1	13
14	PCPP-Adjuvanted Respiratory Syncytial Virus (RSV) sF Subunit Vaccine: Self-Assembled Supramolecular Complexes Enable Enhanced Immunogenicity and Protection. Molecular Pharmaceutics, 2017, 14, 2285-2293.	4.6	28
15	Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits. Vaccine, 2016, 34, 2562-2569.	3.8	23
16	In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant. Cytokine, 2016, 83, 99-109.	3.2	43
17	A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 Activation. PLoS ONE, 2016, 11, e0164632.	2.5	16
18	Local Induction of a Specific Th1 Immune Response by Allergen Linked Immunostimulatory DNA in the Nasal Explants of Ragweed- Allergic Subjects. Allergology International, 2009, 58, 565-572.	3.3	7

JASON D MARSHALL

#	Article	IF	CITATIONS
19	Negative regulation of TLR9-mediated IFN- $\hat{I}\pm$ induction by a small-molecule, synthetic TLR7 ligand. Journal of Leukocyte Biology, 2007, 82, 497-508.	3.3	44
20	Immunostimulatory DNA as a vaccine adjuvant. Expert Review of Vaccines, 2007, 6, 747-759.	4.4	58
21	Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1. Journal of Allergy and Clinical Immunology, 2006, 118, 504-510.	2.9	20
22	CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells. International Immunopharmacology, 2006, 6, 2057-2068.	3.8	4
23	Local and Systemic Effects of Intranodally Injected CpG-C Immunostimulatory-Oligodeoxyribonucleotides in Macaques. Journal of Immunology, 2006, 177, 8531-8541.	0.8	18
24	Induction of interferonâ€Î³ from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoidâ€dendriticâ€cellâ€produced interferonâ€Î± and tumour necrosis factorâ€Î±. Immunology, 2006, 11 38-46.	74.4	67
25	Superior Activity of the Type C Class of ISS In Vitro and In Vivo Across Multiple Species. DNA and Cell Biology, 2005, 24, 63-72.	1.9	61
26	CpG-C Immunostimulatory Oligodeoxyribonucleotide Activation of Plasmacytoid Dendritic Cells in Rhesus Macaques to Augment the Activation of IFN-γ-Secreting Simian Immunodeficiency Virus-Specific T Cells. Journal of Immunology, 2004, 173, 1647-1657.	0.8	67
27	Polymyxin B enhances ISS-mediated immune responses across multiple species. Cellular Immunology, 2004, 229, 93-105.	3.0	27
28	A minimal human immunostimulatory CpG motif that potently induces IFN-Î ³ and IFN-α production. European Journal of Immunology, 2003, 33, 2114-2122.	2.9	47
29	Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. Journal of Leukocyte Biology, 2003, 73, 781-792.	3.3	230
30	Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells. Nucleic Acids Research, 2003, 31, 5122-5133.	14.5	30
31	IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood, 2003, 102, 4487-4492.	1.4	129
32	Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes TH1 cytokine expression while downregulating TH2 cytokine expression in PBMCs from human patients with ragweed allergy. Journal of Allergy and Clinical Immunology, 2001, 108, 191-197.	2.9	130
33	Inhibition of IL-12 Production in Human Monocyte-Derived Macrophages by TNF. Journal of Immunology, 2000, 164, 1722-1729.	0.8	95
34	Expression and Function of IL-12 and IL-18 Receptors on Human Tonsillar B Cells. Journal of Immunology, 2000, 165, 6880-6888.	0.8	103
35	The Interleukin-12–Mediated Pathway of Immune Events Is Dysfunctional in Human Immunodeficiency Virus–Infected Individuals. Blood, 1999, 94, 1003-1011.	1.4	91
36	Regulation of Human IL-18 mRNA Expression. Clinical Immunology, 1999, 90, 15-21.	3.2	62

#	Article	IF	CITATIONS
37	In Vitro Synthesis of IL-4 by Human CD4+ T Cells Requires Repeated Antigenic Stimulation. Cellular Immunology, 1993, 152, 18-34.	3.0	69